Mitochondria-targeted vitamin E analogs inhibit breast cancer cell energy metabolism and promote cell death

Gang Cheng,Jacek Zielonka,Donna M McAllister,A Craig Mackinnon,Joy Joseph,Michael B Dwinell,Balaraman Kalyanaraman

DOI: https://doi.org/10.1186/1471-2407-13-285

IF: 4.638

2013-06-13

BMC Cancer

Abstract:Abstract Background Recent research has revealed that targeting mitochondrial bioenergetic metabolism is a promising chemotherapeutic strategy. Key to successful implementation of this chemotherapeutic strategy is the use of new and improved mitochondria-targeted cationic agents that selectively inhibit energy metabolism in breast cancer cells, while exerting little or no long-term cytotoxic effect in normal cells. Methods In this study, we investigated the cytotoxicity and alterations in bioenergetic metabolism induced by mitochondria-targeted vitamin E analog (Mito-chromanol, Mito-ChM) and its acetylated ester analog (Mito-ChMAc). Assays of cell death, colony formation, mitochondrial bioenergetic function, intracellular ATP levels, intracellular and tissue concentrations of tested compounds, and in vivo tumor growth were performed. Results Both Mito-ChM and Mito-ChMAc selectively depleted intracellular ATP and caused prolonged inhibition of ATP-linked oxygen consumption rate in breast cancer cells, but not in non-cancerous cells. These effects were significantly augmented by inhibition of glycolysis. Mito-ChM and Mito-ChMAc exhibited anti-proliferative effects and cytotoxicity in several breast cancer cells with different genetic background. Furthermore, Mito-ChM selectively accumulated in tumor tissue and inhibited tumor growth in a xenograft model of human breast cancer. Conclusions We conclude that mitochondria-targeted small molecular weight chromanols exhibit selective anti-proliferative effects and cytotoxicity in multiple breast cancer cells, and that esterification of the hydroxyl group in mito-chromanols is not a critical requirement for its anti-proliferative and cytotoxic effect.

oncology

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to develop a new chemotherapy strategy, which inhibits the energy metabolism of breast cancer cells and promotes their death by targeting mitochondrial bioenergetic metabolism in cancer cells. Specifically, the researchers explored the cytotoxic and antiproliferative effects of mitochondrial - targeted vitamin E analogues (such as Mito - chromanol, Mito - ChM and its acetate analogue Mito - ChMAc) on breast cancer cells, and simultaneously evaluated the long - term cytotoxicity of these compounds in normal cells. The goal of the study was to find new drugs that can selectively inhibit the energy metabolism of breast cancer cells without causing significant toxicity to normal cells, so as to improve the chemotherapy effect and reduce side effects. The research background indicates that most malignant tumor cells will undergo energy metabolism reprogramming from oxidative phosphorylation to aerobic glycolysis (Warburg effect). In view of this characteristic, the selective depletion of ATP levels in tumor cells can be achieved by targeting lipophilic, delocalized cationic drugs to mitochondria. However, current chemotherapy methods are often accompanied by significant toxic and side effects. Therefore, there is an urgent need to develop new chemotherapy drugs with less toxicity to normal cells. This paper experimentally verified the selective cytotoxicity and antiproliferative effects of Mito - ChM and Mito - ChMAc in breast cancer cells and explored their potential mechanisms.

Mitochondria-targeted vitamin E analogs inhibit breast cancer cell energy metabolism and promote cell death

Targeting the Mitochondria with Pseudo- Stealthy Nanotaxanes to Impair Mitochondrial Biogenesis for Effective Cancer Treatment

Biological Evaluation of Mitochondria Targeting Small Molecules As Potent Anticancer Drugs.

Mitochondria-Shaping Proteins and Chemotherapy

Mitochondria as a Novel Target for Cancer Chemoprevention: Emergence of Mitochondrial-targeting Agents

Mitochondria-Targeted Ergosterol Peroxide Derivatives: Synthesis, Anticancer Properties and Their Preliminary Mechanism of Inhibiting MCF-7 Cell Proliferation

Mitochondrially targeted vitamin E succinate efficiently kills breast tumour-initiating cells in a complex II-dependent manner

Mitochondrion-Directed Nanoparticles Loaded with a Natural Compound and a microRNA for Promoting Cancer Cell Death via the Modulation of Tumor Metabolism and Mitochondrial Dynamics

[Anti-breast cancer effect of a mitochondrion-targeted derivative of ergosterol peroxide in vitro and in vivo]

Combining PEGylated mito-atovaquone with MCT and Krebs cycle redox inhibitors as a potential strategy to abrogate tumor cell proliferation

Mitochondria Targeted Nanoparticles Potentiate Tumor Chemo-Phototherapy by Toxic Oxidative Stress Mediated Oxeiptosis

Targeting mitochondrial bioenergetics by combination treatment with imatinib and dichloroacetate in human erythroleukemic K‐562 and colorectal HCT‐116 cancer cells

Mitocans Revisited: Mitochondrial Targeting as Efficient Anti-Cancer Therapy

Recent Progress in Mitochondria-Targeted Drug and Drug-Free Agents for Cancer Therapy

Investigating Therapies Targeting Druggable Targets of Mitochondria: Exploring the Efficacy for the Treatment of Cancer

Therapeutic Targeting of the Mitochondria Initiates Excessive Superoxide Production and Mitochondrial Depolarization Causing Decreased mtDNA Integrity

Small Mitochondria-Targeting Molecules As Anti-Cancer Agents

Design and synthesis of novel mitochondria-targeted CDDO derivatives as potential anti-cancer agents

Mitochondria-targeting drug conjugates for cytotoxic, anti-oxidizing and sensing purposes: current strategies and future perspectives

The In Vitro Cytotoxic Effect of Elesclomol on Breast Adenocarcinoma Cells Is Enhanced by Concurrent Treatment with Glycolytic Inhibitors

Preferential killing of cancer cells with mitochondrial dysfunction by natural compounds.